Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Pharma
As IBD sales boom, AbbVie increases Skyrizi, Rinvoq projection
AbbVie has increased its 2027 projected sales for Skyrizi and Rinvoq to a combined $31 billion, a $4 billion increase from prior estimates.
Kevin Dunleavy
Jan 31, 2025 11:41am
New IL-23 UC drugs 'rapidly gained significant momentum': report
Nov 18, 2024 8:55am
Lilly shows restroom rarity affects ulcerative colitis patients
Oct 17, 2024 10:55am
AbbVie’s Skyrizi passes Lilly’s Omvoh to take lead in colitis
Oct 7, 2024 10:53am
Palisade Bio bolsters branding with bold new look
Sep 16, 2024 12:12pm
Tremfya enters crowded ulcerative colitis arena with FDA nod
Sep 11, 2024 6:58pm
